FIG 3.

Pathogenic genomic alterations detected in actionable genes across four major cancer types. Plots include NCCN level 1 (dark purple, bold text) and other ESCAT level II-III genes (light purple, gray text) for (A) NSCLC, (B) prostate cancer, (C) breast cancer, and (D) colon cancer (NCCN/ESCAT genes). An asterisk indicates genes that have a significantly higher proportion of alterations detected in liquid biopsies than tissue biopsies (FDR < 0.001). MMR genes refer to MLH1, MSH2, MSH6, and PMS2. CRC, colorectal cancer; ESCAT, ESMO Scale for Clinical Actionability of Molecular Targets; FDR, false discovery rate; MMR, mismatch repair; MSI-H, high microsatellite instability; NCCN, National Comprehensive Cancer Network; NSCLC, non–small-cell lung cancer.